Skip to content
Triangle logo TriangleGet started
← Study library

NCT03376477 · REGISTRY CONDITION SEARCH

Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
TERMINATED
Registry last update
2025-08-27

This study seeks to determine whether addition of an allogeneic myeloma vaccine can augment clinical responses to lenalidomide in patients with near complete remission (nCR), or complete remission (CR) leading to a significant improvement in progression-free survival.This main objective of this study is to compare the 2-year progression free survival of patients with multiple myeloma in CR or nCR, treated with lenalidomide plus an allogeneic myeloma vaccine in combination with lenalidomide (with or without Prevnar vaccine) or versus placebo in combination with lenalidomide (control arm).

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

2-year Progression Free Survival

→

outcome · POSTED

Response Conversion Rate

→

outcome · POSTED

MRD Conversion Rate

→

outcome · POSTED

Time to Response

→

outcome · POSTED

Progression Free Survival (PFS)

→

outcome · POSTED

Evaluate Toxicity of Allogenic Myeloma Vaccine

→

outcome · POSTED

Measure Tumor Specific Immunity and Correlate With Systemic Immunity

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Myeloma eligibility criteria are the following: * Near complete remission (nCR) for ≥ 3 months defined as no measurable M-spike, and a positive serum immunofixation * For patients with a light chain only myeloma, they will be in deemed to be in a CR if they meet criteria for CR by International Myeloma Working Group (IMWG) consensus criteria 2016. * For patients with a light chain only myeloma that meet criteria for Very Good Partial Response (VGPR) by IMWG consensus criteria 2016 and are IFE -ve (negative serum immunofixation), they will be considered to be in a near complete remission (nCR). * Or complete remission (CR) (no measurable M-spike, immunofixation negative and bone marrow plasma cells \<5%) * NDMM or RMM in nCR or CR having completed a minimum of 6 cycles of a lenalidomide based regimen for a minimum of ≥ 3 months * NDMM or RMM a patients who have been off corticosteroids for ≥ 4 weeks * Patients with NDMM or RMM who have had autologous stem cell transplant are eligible, but must be ≥ 12 months from transplant * All patients must be MRD positive at 10-4 or greater by NGS sequencing at enrollment * All patients must be currently taking Revlimid at screening. * Age \>18 years * ECOG performance scores 0-2 * History of measurable serum or urine M protein or free light chains * Life expectancy greater than 12 months * Corrected serum calcium \< 11 mg/dL, and no evidence of symptomatic hypercalcemia * Serum creatinine\< 2 mg/dl * ANC \>1000/µL * Platelet \>100,000/µL * Total bilirubin \<= 1.5 x ULN * AST (SGOT) and ALT (SGPT) \<= 3 x ULN. * Ability to comprehend and have signed the informed consent. * Have previously agreed to continue on maintenance therapy with lenalidomide concurrent with vaccine administration until disease progression, or clinical indication to cease therapy. * Disease free of prior malignancies for at least 5 years with exception of currently treated basal cell or squamous cell carcinoma of the skin, or carcinoma "in situ" of the uterus, cervix or breast. * All study participants must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of the REMS® program. * Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program. * Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to starting lenalidomide with each cycle (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. * Able to take prophylactic anticoagulation (aspirin 81 or 325 mg/daily or, for patients intolerant to ASA, warfarin or low molecular weight heparin). Exclusion Criteria: * Disease progression after stopping corticosteroids as defined as the appearance of a detectable serum or urine M-spike, or an absolute increase of \>10 mg/dl between involved and uninvolved light chains, in the absence of measurable serum or urine M-protein . * Patients who are MRD negative by NGS at screening. * Patients with a known diagnosis of POEMS syndrome, plasma cell leukemia, CNS involvement, non-secretory myeloma and amyloidosis * High-risk myeloma defined by presence of at least one of the following defining features on initial diagnostic, or most recent bone marrow biopsy: * High risk chromosomal translocations by FISH: t(4;14), t(14;16), t(14;20), * del(17p), del(1p), amplification 1q.; * MyPRS GEP-70 high risk signature either from diagnosis or at time of registration for the study; * LDH \> 300 U/L at diagnosis; * Relapse from prior therapy within 12 months. * HIV disease, active infection requiring treatment with antibiotics, anti-fungal or anti-viral agents within 2 weeks of enrollment would be excluded from the study. * Patients who have participated in any clinical trial, within the last four weeks, which involved an investigational drug. * History of an active malignancy other than myeloma * Autoimmune disease requiring active treatment. * Known contra-indication to any component of allogeneic myeloma vaccine * History of an allogeneic transplant
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment. Patients assigned to vaccine therapy will receive injections on day 14 (+/-3 days) of cycles 1, 2, 3 and 6 from enrollment, and then annually thereafter. Prevnar vaccine will be administered with the GM-CSF vaccine administration.
    intervention Names
    1. Biological: GM-CSF vaccine
    2. Drug: Lenalidomide
    3. Drug: Prevnar13
    label
    Lenalidomide plus GM-CSF Vaccine plus Prevnar13
    type
    EXPERIMENTAL
  2. description
    Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment. Patients will also get placebo GM-CSF vaccine and placebo prevnar13. Placebo will be saline.
    intervention Names
    1. Drug: Lenalidomide
    2. Other: Placebo Prevnar13
    3. Other: Placebo GM-CSF Vaccine
    label
    Lenalidomide Only
    type
    PLACEBO_COMPARATOR
  3. description
    Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment. Patients assigned to vaccine therapy will receive injections on day 14 (+/-3 days) of cycles 1, 2, 3 and 6 from enrollment, and then annually thereafter. Patients will also be administered a placebo prevnar13 vaccination. Placebo will be saline.
    intervention Names
    1. Biological: GM-CSF vaccine
    2. Drug: Lenalidomide
    3. Other: Placebo Prevnar13
    label
    Lenalidomide plus GM-CSF Vaccine
    type
    PLACEBO_COMPARATOR
interventions
  1. arm Group Labels
    1. Lenalidomide plus GM-CSF Vaccine
    2. Lenalidomide plus GM-CSF Vaccine plus Prevnar13
    description
    Each vaccination will consist of three total intra-dermal injections, on day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). In the event that the specified limb is contraindicated, the dominant arm may be used. Vaccine injection sites shall be at least 5 cm at needle entry from the nearest neighbor. The approximate volume of each vaccination injection is approximately 0.7-0.8ml.
    name
    GM-CSF vaccine
    other Names
    1. GVAX
    type
    BIOLOGICAL
  2. arm Group Labels
    1. Lenalidomide Only
    2. Lenalidomide plus GM-CSF Vaccine
    3. Lenalidomide plus GM-CSF Vaccine plus Prevnar13
    description
    Patients will be continued on the same dose of lenalidomide as they were prior to being enrolled in the study. Doses of lenalidomide for investigation can vary from 5-25 mg/day, orally on days 1 - 21 followed by 7 days rest (28 day cycle).
    name
    Lenalidomide
    other Names
    1. Revlimid
    type
    DRUG
  3. arm Group Labels
    1. Lenalidomide plus GM-CSF Vaccine plus Prevnar13
    description
    Prevnar will be administered at the same time points as the GM-CSF vaccine (day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months), but on the opposite arm from GM-CSF vaccine.
    name
    Prevnar13
    other Names
    1. pneumococcal vaccine
    type
    DRUG
  4. arm Group Labels
    1. Lenalidomide Only
    2. Lenalidomide plus GM-CSF Vaccine
    description
    Saline will be used for placebo. Placebo prevnar will be administered at the same time points as the GM-CSF vaccine or Placebo GM-CSF Vaccine (day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months), but on the opposite arm from GM-CSF vaccine or placebo GM-CSF vaccine.
    name
    Placebo Prevnar13
    type
    OTHER
  5. arm Group Labels
    1. Lenalidomide Only
    description
    Saline will be used for placebo. Each placebo vaccine will consist of three total intra-dermal injections on day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). In the event that the specified limb is contraindicated, the dominant arm may be used. Placebo injection sites shall be at least 5 cm at needle entry from the nearest neighbor. The approximate volume of each injection is approximately 0.7-0.8ml.
    name
    Placebo GM-CSF Vaccine
    type
    OTHER
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
intervention Model Description
All patients will continue on a standard dose of lenalidomide. Patients on the myeloma vaccine arm will receive injections in addition to lenalidomide unless otherwise clinically indicated, or until progression. Patients on myeloma plus Prevnar vaccine arm will receive injections of both allogenic myeloma vaccine and Prevnar vaccine in addition to lenalidomide unless otherwise clinically indicated, or until progression. Patients on the myeloma vaccine placebo arm will receive myeloma vaccine placebo on the same schedule as allogeneic myeloma vaccine. If assigned to either of the two arms that do not include Prevnar, then patients will receive placebo in lieu of Prevnar on the same schedule. The placebo will be saline. All patients will be followed for a minimum of 3 years.
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
24
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Number of participants without disease progression at 2 years.
    measure
    2-year Progression Free Survival
    time Frame
    2 years
secondary Outcomes
  1. description
    Number of participants who converted from near complete remission (nCR) to complete remission (CR) as measured by the International Myeloma Working Group Uniform Response Criteria. Near complete remission is defined as negative serum and urine electrophoresis, \< 5% plasma cells in the bone marrow, and positive serum and/or urine immunofixation. Complete response is defined as negative serum and urine immunofixation and a bone marrow aspirate with \< 5% plasma cells.
    measure
    Response Conversion Rate
    time Frame
    2 years
  2. description
    Number of participants who convert from MRD (Minimal Residual Disease) positive status to MRD negative status as determined through next generation sequencing (NGS).
    measure
    MRD Conversion Rate
    time Frame
    2 years
  3. description
    Median time for conversion of response from near complete remission (nCR) to complete remission (CR) as measured by the International Myeloma Working Group Uniform Response Criteria. Near complete remission is defined as negative serum and urine electrophoresis, \< 5% plasma cells in the bone marrow, and positive serum and/or urine immunofixation. Complete response is defined as negative serum and urine immunofixation and a bone marrow aspirate with \< 5% plasma cells as measured by immunofixation converting from positive to negative.
    measure
    Time to Response
    time Frame
    2 Years
  4. description
    Number of months without disease progression.
    measure
    Progression Free Survival (PFS)
    time Frame
    3 and 5 years
  5. description
    Number of participants experiencing adverse events grade 3 or higher, as defined by Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0)
    measure
    Evaluate Toxicity of Allogenic Myeloma Vaccine
    time Frame
    3 years
  6. measure
    Measure Tumor Specific Immunity and Correlate With Systemic Immunity
    time Frame
    3 years
Full study description
brief Summary
This study seeks to determine whether addition of an allogeneic myeloma vaccine can augment clinical responses to lenalidomide in patients with near complete remission (nCR), or complete remission (CR) leading to a significant improvement in progression-free survival.This main objective of this study is to compare the 2-year progression free survival of patients with multiple myeloma in CR or nCR, treated with lenalidomide plus an allogeneic myeloma vaccine in combination with lenalidomide (with or without Prevnar vaccine) or versus placebo in combination with lenalidomide (control arm).
detailed Description
This is a single institution, three- arm, randomized controlled, Phase II study examining the clinical efficacy of an allogeneic GM-CSF secreting myeloma vaccine in combination with lenalidomide (with or without Prevnar) compared to lenalidomide and placebo (control arm). Patients enrolled in the study must have two disease measurements (including the last one) consistent with a near complete remission (M-spike negative with persistence of immunofixation), or complete remission (M-spike negative, negative immunofixation, and \<5% clonal plasma cells on bone marrow) per criteria for response in a 3 month period. All patients must be minimal residual disease (MRD) positive by NGS sequencing at enrollment. Prior to enrollment, patients will have been treated with a lenalidomide containing regimen for a minimum of 6 cycles. All patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment. Patients will be randomized to receive either an allogeneic myeloma vaccine and Prevnar vaccine in combination with lenalidomide, or allogeneic myeloma vaccine without Prevnar vaccine in combination with lenalidomide, or lenalidomide in combination with placebo. Patients will receive allogeneic myeloma vaccine or placebo injections on day 14 (+/-3 days) of cycles 1, 2, 3 and 6 from enrollment, and then annually thereafter for up to 3 years. If assigned to allogeneic myeloma vaccine plus Prevnar vaccine arm, Prevnar-13 will be administered with each allogeneic myeloma vaccine. If assigned to either of the two arms that do not include Prevnar, then patients will receive a placebo in lieu of Prevnar on the same schedule. All patients will be followed for a minimum of 3 years.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-1044baeff59e42d062f2
      requested nct id
      NCT03376477
      primary nct id
      NCT03376477
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      f14099922485985fde28d7dd519d690d0e054c5f1ed9daaa7890f389735bc35b
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-1044baeff59e42d062f2
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT03376477
      occurrences
      1. context exact
        NCT03376477
        end
        11
        exact text
        NCT03376477
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/218/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      041bc0e57e87060d95298e8de53999b6a67b4214b44cad0ff0c87a1c24912316

    Preserved source evidence · Not medical advice